...
首页> 外文期刊>The Journal of Urology >Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
【24h】

Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.

机译:CYFRA 21-1诊断性能作为膀胱移行细胞癌中尿液指标的初步评估。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: CYFRA 21-1, an immunoradiometric assay developed for the detection of a soluble cytokeratin 19 fragment, is evaluated for its diagnostic performance in urine of patients with transitional cell carcinoma. MATERIALS AND METHODS: CYFRA 21-1 was investigated in serum and urine of 128 patients, including 48 with bladder transitional cell carcinoma (group 1), 44 with other urological pathological conditions (group 2) and 36 free of urothelial disease (group 3). Urinary cytopathology was also performed. RESULTS: Mean urinary CYFRA was 123.5 +/- 53, 11.9 +/- 4.8 and 2.3 +/- 0.2 ng./ml. for groups 1 to 3, respectively, and was significantly different. From the receiver operating characteristics curve, the optimal combination of 96% sensitivity and 74% specificity was determined for a threshold value of 4 ng./ml. while overall cytopathology sensitivity was 43%. CONCLUSIONS: Urinary CYFRA 21-1 may be a useful marker for diagnosing transitional cell carcinoma.
机译:目的:开发用于检测可溶性细胞角蛋白19片段的免疫放射测定法CYFRA 21-1,以评估其在移行细胞癌患者尿液中的诊断性能。材料与方法:研究人员对128例患者的血清和尿液中的CYFRA 21-1进行了研究,其中48例患有膀胱移行细胞癌(第1组),44例患有其他泌尿病理疾病(第2组)和36例无尿路上皮疾病(第3组) 。还进行了尿液细胞病理学检查。结果:平均尿CYFRA为123.5 +/- 53、11.9 +/- 4.8和2.3 +/- 0.2 ng./ml。对于第1至3组,分别存在显着差异。从接收器的工作特性曲线中,可以确定阈值为4 ng./ml的96%灵敏度和74%特异性的最佳组合。而总体细胞病理学敏感性为43%。结论尿CYFRA 21-1可能是诊断移行细胞癌的有用标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号